Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

doxorubicin liposome

Known as: pegylated liposomal doxorubicin, Liposomal Doxorubicin, doxorubicin liposomal 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
In metastatic breast cancer (MBC), the conventional doxorubicin (DOX) has various problems due to lack of selectivity with… Expand
Highly Cited
2017
Highly Cited
2017
Background:Pembrolizumab (P) is an anti-PD-1 antibody that blocks the interaction between programmed cell death protein 1 (PD-1… Expand
  • table 1
  • table 2
  • table 2
  • table 3
  • table 4
2017
2017
PHSCN peptide (licensed as ATN-161) is an effective α5β1 integrin inhibitor that has advanced to phase II clinical trials to… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
2016
2016
BackgroundAcquired drug resistance is the greatest obstacle to the successful treatment of multiple myeloma (MM). Despite recent… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
ABSTRACT Hydroxychloroquine (HCQ) inhibits autophagy and therefore can sensitize some cancer cells to chemotherapy, but the high… Expand
2015
2015
BACKGROUND Mesenchymal/metaplastic breast cancers (MpBCs) are often triple-negative (TNBC), and chemo-refractory, and can harbor… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
2013
2013
BACKGROUND Despite improvement with intensive multi-agent chemotherapy, 2-year progression-free survival (PFS) rates for adults… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
2011
2011
Stealth liposomes form an important subset of liposomes, demonstrating prolonged circulation half-life and improved safety in… Expand
2010
2010
BackgroundPlatinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This… Expand
  • table 1
  • table 2
  • table 3
Highly Cited
2006
Highly Cited
2006
5006 Background: Bevacizumab (BV), a recombinant, humanized monoclonal antibody directed against vascular endothelial growth… Expand